よむ、つかう、まなぶ。
【参考資料２－３】抗微生物薬適正使用の手引き 第四版（案）薬剤耐性菌感染症の抗菌薬適正使用編 (99 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_64503.html |
| 出典情報 | 厚生科学審議会 感染症部会（第99回 10／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
抗微生物薬適正使用の手引き
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
166. Soueges S, et al. G2I (Groupe Immunodepression et Infections) network. Real-world
multicentre study of cefiderocol treatment of immunocompromised patients with
infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. J Infect.
2025. 90(1):106376.
5
6
167. Muder RR, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a
prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996. 22(3):508-12.
7
8
9
168. Araoka H, et al. Evaluation of trimethoprim-sulfamethoxazole based combination therapy
against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer
patients. Int J Infect Dis. 2017. 58:18-21.
10
11
12
169. Shah MD, et al. Efficacy of combination therapy versus monotherapy in the treatment of
Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother. 2019. 74(7):20552059.
13
14
15
16
170. Chen L, et al. Assessment of the relative benefits of monotherapy and combination
therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia
pneumonia: a multicenter, observational, real-world study. Ann Intensive Care. 2023.
13(1):47.
17
18
19
171. Biagi M, et al. Activity of Potential Alternative Treatment Agents for Stenotrophomonas
maltophilia Isolates Nonsusceptible to Levofloxacin and/or TrimethoprimSulfamethoxazole. J Clin Microbiol. 2020. 58(2):e01603-19.
20
21
22
172. Mojica MF, et al. Population Structure, Molecular Epidemiology, and β-Lactamase
Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio.
2019. 10(4):e00405-19.
23
24
173. Harris H, et al. Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam
Broth Disk Elution Test. J Clin Microbiol. 2023. 61(5):e0164722.
25
26
27
174. Morrissey I, et al. In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated
in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother.
2020. 64(3):e01699-19.
28
29
30
31
175. Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of
America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021
Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.
Clin Infect Dis. 2021. 73(5):755-757.
32
33
34
176. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社
団法人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
35
36
37
177. van Prehn J, et al. European Society of Clinical Microbiology and Infectious Diseases:
2021 update on the treatment guidance document for Clostridioides difficile infection in
adults. Clin Microbiol Infect. 2021. 27 Suppl 2:S1-S21.
38
39
178. Fitzpatrick F, et al. How can patients with Clostridioides difficile infection on concomitant
antibiotic treatment be best managed? Lancet Infect Dis. 2022. 22(11):e336-e340.
40
41
42
179. Slimings C, et al. Antibiotics and healthcare facility-associated Clostridioides difficile
infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother.
2021. 76(7):1676-1688.
43
99
第四版
薬剤耐性菌感染症の抗菌薬適正使用編
1
2
3
4
166. Soueges S, et al. G2I (Groupe Immunodepression et Infections) network. Real-world
multicentre study of cefiderocol treatment of immunocompromised patients with
infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID. J Infect.
2025. 90(1):106376.
5
6
167. Muder RR, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a
prospective, multicenter study of 91 episodes. Clin Infect Dis. 1996. 22(3):508-12.
7
8
9
168. Araoka H, et al. Evaluation of trimethoprim-sulfamethoxazole based combination therapy
against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer
patients. Int J Infect Dis. 2017. 58:18-21.
10
11
12
169. Shah MD, et al. Efficacy of combination therapy versus monotherapy in the treatment of
Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother. 2019. 74(7):20552059.
13
14
15
16
170. Chen L, et al. Assessment of the relative benefits of monotherapy and combination
therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia
pneumonia: a multicenter, observational, real-world study. Ann Intensive Care. 2023.
13(1):47.
17
18
19
171. Biagi M, et al. Activity of Potential Alternative Treatment Agents for Stenotrophomonas
maltophilia Isolates Nonsusceptible to Levofloxacin and/or TrimethoprimSulfamethoxazole. J Clin Microbiol. 2020. 58(2):e01603-19.
20
21
22
172. Mojica MF, et al. Population Structure, Molecular Epidemiology, and β-Lactamase
Diversity among Stenotrophomonas maltophilia Isolates in the United States. mBio.
2019. 10(4):e00405-19.
23
24
173. Harris H, et al. Evaluation of an MIC-Based Aztreonam and Ceftazidime-Avibactam
Broth Disk Elution Test. J Clin Microbiol. 2023. 61(5):e0164722.
25
26
27
174. Morrissey I, et al. In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated
in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother.
2020. 64(3):e01699-19.
28
29
30
31
175. Johnson S, et al. Clinical Practice Guideline by the Infectious Diseases Society of
America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021
Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults.
Clin Infect Dis. 2021. 73(5):755-757.
32
33
34
176. Clostridioides difficile 感染症診療ガイドライン 公益社団法人日本化学療法学会・一般社
団法人日本感染症学会 CDI 診療ガイドライン作成委員会編. 2022. at
https://www.kansensho.or.jp/uploads/files/guidelines/guideline_cdi_230125.pdf.)
35
36
37
177. van Prehn J, et al. European Society of Clinical Microbiology and Infectious Diseases:
2021 update on the treatment guidance document for Clostridioides difficile infection in
adults. Clin Microbiol Infect. 2021. 27 Suppl 2:S1-S21.
38
39
178. Fitzpatrick F, et al. How can patients with Clostridioides difficile infection on concomitant
antibiotic treatment be best managed? Lancet Infect Dis. 2022. 22(11):e336-e340.
40
41
42
179. Slimings C, et al. Antibiotics and healthcare facility-associated Clostridioides difficile
infection: systematic review and meta-analysis 2020 update. J Antimicrob Chemother.
2021. 76(7):1676-1688.
43
99